Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Recruiting now · Phase 2
Conditions studied: B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
In brief
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.
Key facts
- Study ID
- NCT06526793
- Run by
- AstraZeneca
- People needed
- 270
- Starts
- 2024-11-27
- Expected to finish
- 2032-10-21
- Last updated by the study team
- 2026-06-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Brampton, Ontario, Canada (enrolling)
- Research Site — Toronto, Ontario, Canada (enrolling)
- Research Site — Macquarie University, Australia (enrolling)
- Research Site — São Paulo, Brazil (enrolling)
- Research Site — Ottawa, Ontario, Canada (enrolling)
- Research Site — Waukee, Iowa, United States (enrolling)
- Research Site — Tampa, Florida, United States (enrolling)
- Research Site — Duarte, California, United States (enrolling)
- Research Site — Chicago, Illinois, United States (enrolling)
- Research Site — São Paulo, Brazil (enrolling)
- Research Site — New York, New York, United States (enrolling)
- Research Site — Charlotte, North Carolina, United States (enrolling)
- Research Site — Columbus, Ohio, United States (enrolling)
- Research Site — Portland, Oregon, United States (enrolling)
- Research Site — Philadelphia, Pennsylvania, United States (enrolling)
- Research Site — Pittsburgh, Pennsylvania, United States (enrolling)
- Research Site — Rochester, Minnesota, United States (enrolling)
- Research Site — Nashville, Tennessee, United States (enrolling)
- Research Site — Austin, Texas, United States (enrolling)
- Research Site — Houston, Texas, United States (enrolling)
- Research Site — Nedlands, Australia (enrolling)
- Research Site — Milwaukee, Wisconsin, United States (enrolling)
- Research Site — Heidelberg, Australia (enrolling)
- Research Site — Kogarah, Australia (enrolling)
- Research Site — Chengdu, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.